V. 47. P. 1435-1441.
Paulus W., Trenkwalder C. Pathophysiology of dopaminergic therapy - related augmentationin rextlesslegs syndrome / / Lancet Neurology, 2006. V. 5. P. 878-886.
Phillips B., Young T., Finn L. et al. Epidemiology of restless legs symptoms in adults / / Arch. Int. Med., 2000. V.160. P. 2137-2141.
Saletu M., Anderer P., Saletu-Zyhlarz G. et al. Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) acute placebo-controlled sleep laboratory studies with clonazepam / / Eur. Neuropsychopharmacol., 2001. V. 11. P. 153-161.
Silber M. H., Ehrenberg B. L., Allen R. P. et al. An algorithm for the? Management of restless legs syndrome / / Mayo Clin Proc., 2004. V. 79. P. 916-922.
Steiner JC Clonidine helps restless legs syndrome / / Neurology, 1987. V. 37 (Suppl. 1). P. 278.
Trenkwalder C., Henning WA, Walters AS et al. Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome / / Mov. Disord., 1999. V.14. P. 102-110.
Turjanski N., Lees AJ, Brooks DJ Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies / / Neurology, 1999. V.52. P. 932-937.
Ulfberg J., Nystrom B., Carter N. et al. Prevalence of restless legs syndrome among men aged 18 to 64 years: an? Association with somatic disease and neuropsychiatric symptoms / / Mov. Disord., 2001. V. 16. P. 1159-1163.
Walker SL, Fine A., Kryger MH L-DOPA/carbidopa for nocturnal movement disorders in uremia / / Sleep, 1996. V.19.
P. 214-218.
Для підготовки даної роботи були використані матеріали з сайту lvrach
Дата додавання: 22.04.2014
